Article
Acute myeloid leukemia: current progress and future directions.
Blood cancer journal - 22 Feb 2021
Kantarjian Hagop, Kadia Tapan, DiNardo Courtney, Daver Naval, Borthakur Gautam, Jabbour Elias, Garcia-Manero Guillermo, Konopleva Marina, Ravandi Farhad
Abstract excerpt
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve...
Topics
- Animals
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Chromosome Aberrations
- Disease Management
- Humans
- Leukemia, Myeloid, Acute
- Molecular Targeted Therapy
- Mutation
- Prognosis